HDFC Q1 preview: Profit expected to fall

IDBI Capital Markets & Securities expects a 44 percent year-on-year (YoY) fall in HDFC's Q1 PAT while it expects the NBFC lender's NII to rise 12.5 percent.

Non-banking financial heavyweight HDFC will release its June quarter numbers on July 30 in which it is likely to report a rise in net interest income (NII), but PAT may see a decline.

Other than the numbers, the outlook on asset quality, especially on non-individual loans and moratorium books will be in the focus.

IDBI Capital Markets & Securities (a wholly-owned subsidiary of IDBI Bank) expects a 44 percent year-on-year (YoY) fall in HDFC's Q1 PAT while it expects the NBFC lender's NII to rise 12.5 percent.

Brokerage firm Motilal Oswal Financial Services expects a 9 percent YoY AUM growth for the company driven by non-retail lending.

The brokerage sees an incremental cost of funds at nearly 6 percent from capital markets. HDFC's Q1 PAT, as per Motilal Oswal, may fall 26 percent YoY.

Motilal expects a 6.9 percent YoY growth in HDFC's Q1 NII. However, core income may see a mild drop of 0.6 percent YoY.

Core operating profits and core PBT may slip by 0.4 percent and 0.6 percent YoY, respectively.

On the other hand, Kotak Institutional Equities expects HDFC to report a 10 percent YoY growth in NII while NIM may slip 5 bps YoY.

HDFC's provisions may see a rise of 39.3 percent YoY and PAT is likely to drop 7.5 percent YoY, Kotak said.

As per Kotak, HDFC booked capital gains of Rs 1,240 crore on stake sale in HDFC Life and the brokerage expects the company to make equivalent provisions to boost its ECL coverage.

Dividend income of Rs 298 crore, which was nil in Q1FY20, and fair value gain of Rs 33.4 crore against the loss of Rs 45 crore in Q1FY20, will likely support earnings, Kotak said.

Disclaimer:

Source - Moneycontrol.com

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...

SD Solutions

Search This Blog